Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Lloyd Mitchell Segal Sells 2,650 Shares of Stock

Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Lloyd Mitchell Segal sold 2,650 shares of Repare Therapeutics stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $4.63, for a total transaction of $12,269.50. Following the completion of the transaction, the chief executive officer now owns 83,866 shares of the company’s stock, valued at approximately $388,299.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Lloyd Mitchell Segal also recently made the following trade(s):

• On Monday, March 25th, Lloyd Mitchell Segal sold 2,650 shares of Repare Therapeutics stock. The shares were sold at an average price of $4.79, for a total transaction of $12,693.50.

Repare Therapeutics Stock Performance

RPTX opened at $4.67 on Thursday. The company has a fifty day moving average price of $6.33 and a two-hundred day moving average price of $6.60. Repare Therapeutics Inc. has a 52 week low of $3.08 and a 52 week high of $13.85. The firm has a market capitalization of $172.79 million, a PE ratio of -2.09 and a beta of 0.62.

Repare Therapeutics (NASDAQ:RPTX) last released its earnings results on Wednesday, February 28th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.11). Repare Therapeutics had a negative return on equity of 39.82% and a negative net margin of 183.43%. The business had revenue of $13.05 million for the quarter, compared to analyst estimates of $15.92 million. Equities analysts forecast that Repare Therapeutics Inc. will post -2.74 EPS for the current year.

Analyst Upgrades and Downgrades

RPTX has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a report on Wednesday, February 21st. Bloom Burton lowered shares of Repare Therapeutics from a “buy” rating to an “accumulate” rating in a report on Tuesday, February 13th.

Hedge Funds Weigh In On Repare Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RPTX. Blue Owl Capital Holdings LP acquired a new position in shares of Repare Therapeutics in the 4th quarter valued at $22,794,000. BVF Inc. IL lifted its position in Repare Therapeutics by 24.6% in the 4th quarter. BVF Inc. IL now owns 10,333,600 shares of the company’s stock valued at $75,435,000 after acquiring an additional 2,041,612 shares in the last quarter. Bank of America Corp DE lifted its position in Repare Therapeutics by 1,913.0% in the 4th quarter. Bank of America Corp DE now owns 260,886 shares of the company’s stock valued at $3,838,000 after acquiring an additional 247,926 shares in the last quarter. ARK Investment Management LLC lifted its position in Repare Therapeutics by 7.7% in the 4th quarter. ARK Investment Management LLC now owns 2,821,560 shares of the company’s stock valued at $20,597,000 after acquiring an additional 200,677 shares in the last quarter. Finally, Affinity Asset Advisors LLC lifted its position in Repare Therapeutics by 72.5% in the 1st quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company’s stock valued at $6,677,000 after acquiring an additional 197,127 shares in the last quarter. Institutional investors and hedge funds own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.